Free Trial

500,000 Shares in Aardvark Therapeutics, Inc. $AARD Purchased by Braidwell LP

Aardvark Therapeutics logo with Medical background

Key Points

  • Braidwell LP purchased 500,000 shares of Aardvark Therapeutics, Inc. for about $3.76 million, now holding around 2.30% of the company.
  • Analysts have mixed views on Aardvark Therapeutics, with target prices ranging from $19.00 to $40.00, and an average rating of "Buy" according to recent reports.
  • Aardvark's stock price opened at $8.30, with a one-year low of $4.88 and a high of $19.58, while the company recently reported a quarterly earnings loss of $0.66 per share.
  • MarketBeat previews top five stocks to own in October.

Braidwell LP bought a new position in Aardvark Therapeutics, Inc. (NASDAQ:AARD - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 500,000 shares of the company's stock, valued at approximately $3,755,000. Braidwell LP owned about 2.30% of Aardvark Therapeutics at the end of the most recent quarter.

Separately, Walleye Capital LLC purchased a new stake in Aardvark Therapeutics in the first quarter worth approximately $88,000.

Aardvark Therapeutics Stock Performance

Shares of NASDAQ AARD traded up $0.11 during midday trading on Friday, reaching $8.60. The stock had a trading volume of 139,793 shares, compared to its average volume of 87,039. The stock has a 50-day moving average of $11.52 and a 200-day moving average of $10.79. Aardvark Therapeutics, Inc. has a 12-month low of $4.88 and a 12-month high of $19.58.

Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.14).

Analysts Set New Price Targets

AARD has been the topic of a number of recent research reports. Royal Bank Of Canada lowered their target price on Aardvark Therapeutics from $20.00 to $19.00 and set an "outperform" rating on the stock in a report on Thursday, August 14th. HC Wainwright initiated coverage on shares of Aardvark Therapeutics in a report on Monday, June 30th. They set a "buy" rating and a $40.00 target price for the company. Wall Street Zen cut shares of Aardvark Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, June 14th. Finally, Bank of America cut their price objective on shares of Aardvark Therapeutics from $26.00 to $25.00 and set a "buy" rating for the company in a research report on Thursday, August 28th. Five analysts have rated the stock with a Buy rating, According to MarketBeat, Aardvark Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $32.60.

Check Out Our Latest Stock Analysis on AARD

Aardvark Therapeutics Company Profile

(Free Report)

Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

See Also

Institutional Ownership by Quarter for Aardvark Therapeutics (NASDAQ:AARD)

Should You Invest $1,000 in Aardvark Therapeutics Right Now?

Before you consider Aardvark Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aardvark Therapeutics wasn't on the list.

While Aardvark Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.